Dr. Piperdi on Immunotherapy in Lung Cancer
Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, discusses the potential of immunotherapy for the treatment of patients with lung cancer.
Piperdi says initial data on immunotherapy agents for lung cancer treatment is encouraging. In addition to responses, these agents seem to be improving long-term survival, even in refractory patients.
It remains to be seen how these agents will interact with standard treatments, including chemotherapy and radiation. However, Piperdi thinks combining immunotherapy agents with targeted agents is going to be the greatest area of interest and benefit over the next couple of years.